**NCI CIRB**

**REVIEWER WORKSHEET**

**CIRB Review of Participant Materials**

 OMB#0925-0753 Expiration Date: 05/31/2027

The purpose of the information collection is to conduct reviews of clinical trial studies.  NCI guidelines mandate the participation of institutions in the CIRB for Network group studies.  You are being requested to complete this instrument so that we can conduct activities involved with the operations of the NCI CIRB Initiative.  Although your participation in Network group research and completion of the forms is voluntary, if you wish to participate in the CIRB, you must complete all questions on the form.  The information you provide will be combined for all participants and reported as summaries.  It will be kept private to the extent provided by law.

**NOTIFICATION TO RESPONDENT OF ESTIMATED BURDEN**

Public reporting burden for this collection of information is estimated to average 15 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. **An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number.** Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to: NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA (0925-0753). Do not return the completed form to this address.

**STUDY ID:** $$Study ID$$

**STUDY TITLE:** $$Study Title$$

**NAME OF CIRB REVIEWER:** $$Primary Reviewer$$

 **DATE COMPLETED:**

**Reminder to reviewers:** Participant materials should be reviewed for the following three components:

* accuracy of the information presented,
* to ensure that the material is not coercive, and
* to ensure that the material does not promise a certainty of cure or benefit beyond what is outlined in the informed consent document and the protocol.

Remember that potential study participants will be given a consent document providing greater detail on the study and its foreseeable risks and benefits.

**1. Indicate the documents reviewed (check all that apply):**

[ ]  Updated NCI CIRB Application for Treatment Studies

[ ]  Summary of CIRB Application revisions

[ ]  Participant Material. Indicate the material reviewed:

[ ]  Pamphlets

[ ]  Webpage

[ ]  Video Script

[ ]  QOLs/PROs

[ ]  Other:

**2. Is a distribution plan provided (see section 5.2 of the CIRB Application)?**

[ ]  Yes. If yes, briefly describe the plan:

[ ]  No. If no, a distribution plan is required before the participant material can be approved.

**3. Does the participant material include any exculpatory language?**

Exculpatory language is “language through which the subject or the representative is made to waive or appear to waive any of the subject's legal rights, or releases or appears to release the investigator, the sponsor, the institution or its agents from liability for negligence.” (45 CFR 46.116). Examples of exculpatory language can be found in the 1996 OPRR Letter “Exculpatory Language in Informed Consent Documents: Examples of Acceptable and Unacceptable Language” available at: http://www.hhs.gov/ohrp/policy/exculp.html.

[ ]  Yes. If yes, identify the language and provide suggested revisions:

[ ]  No.

**4. Does the participant material state or imply a certainty of a favorable outcome or other benefits beyond what is outlined in the informed consent document and protocol?**

[ ]  Yes. If yes, identify the language and provide suggested revisions:

[ ]  No.

**5. Does the participant material include language that in any way appears to place undue influence on the potential study participant to enroll in the study? (i.e. access to free drugs or treatment, compensation, etc).**

[ ]  Yes. If yes, identify the language and provide suggested revisions:

[ ]  No.

**6. Does the participant material suggest that the investigational article is safe, effective, equivalent, or superior to other options?**

[ ]  Yes. If yes, identify the language and provide suggested revisions:

[ ]  No.

**7. Does the participant material refer to an investigational drug, biologic or device as a “new drug” or “new treatment” without explaining that the test article is investigational?**

[ ]  Yes. If yes, identify the language and provide suggested revisions:

[ ]  No.

**8. Does the participant material emphasize any payment to be made to subjects or compensation for participation in the study?**

Note that NCI-Sponsored research generally does not provide compensation for participation in a study. Nonetheless, if compensation is offered, it may be noted in recruitment materials but should not be emphasized over other elements of the material.

[ ]  Yes. If yes, identify the language and provide suggested revisions:

[ ]  No.

**9. Does the participant material promise “free treatment” when the intent is only to say participants will not be charged for taking part in the study?**

[ ]  Yes. If yes, identify the language and provide suggested revisions:

[ ]  No.

**10. Recommendation to the CIRB**
If a distribution plan is provided (per question 2) and there are no changes required to language in the **participant** materials (per questions 3 through 8) the recruitment material may be approved.

[ ]  **Approve**

A distribution plan is provided and there are no required or suggested revisions.

[ ]  **Approve Pending Modifications**

There are required changes to the **participant** materials (per questions 3 through 9).

[ ]  **Table**

There is insufficient information available to make a determination regarding the **participant** material, or substantive changes are required and warrants re-review by the convened CIRB.

[ ]  **Disapprove**

The submitted material is inaccurate and does not meet the regulatory and CIRB SOP requirements for approval.

**11.** **Comments**